美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Eikon Therapeutics

9.74

+0.38004.06%

成交量：59.71萬

成交額：577.28萬

市值：5.26億

市盈率：-1.64

高：10.24

開：9.33

低：9.08

收：9.36

52周最高：17.40

52周最低：7.90

股本：5,398.43萬

流通股本：1,764.80萬

量比：0.91

換手率：3.38%

股息：- -

股息率：- -

每股收益(TTM):-5.9500

每股收益(LYR):-115.2900

淨資產收益率：-125.02%

總資產收益率：-36.19%

市淨率：1.13

市盈率(LYR):-0.08

資料載入中...

總覽公司新聞資訊公告

營收暴增無阻英派藥業繼續虧損：預計上半年減虧三成左右！股價早已破發

深圳商报·读创

Eikon Therapeutics宣佈晚期黑色素瘤Eik1001適應症2/3期試驗Teluride-006進入劑量選擇階段

Eikon Therapeutics宣佈Teluride-008臨床試驗首位患者給藥，Eik1001用於非小細胞肺癌的註冊性II/III期研究正式啓動

新聞稿：Eikon Therapeutics 宣佈任命 Ma. Fatima D. Francisco 加入董事會

Eikon Therapeutics公布2025年第四季度及全年財報同步更新臨床進展與企業動態

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/EIKN/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EIKN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":9.74,"timestamp":1789500318643,"preClose":9.36,"halted":0,"volume":597070,"delay":0,"changeRate":0.04059829059829068,"floatShares":17648000,"shares":53984300,"eps":-5.95,"marketStatus":"交易中","change":0.38,"latestTime":"09-15 15:25:23 EDT","open":9.33,"high":10.24,"low":9.075,"amount":5772834.58442,"amplitude":0.124466,"askPrice":9.75,"askSize":178,"bidPrice":9.73,"bidSize":130,"shortable":3,"etf":0,"ttmEps":-5.95,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":9.36,"preHourTrading":{"tag":"盘前","latestPrice":9.51,"preClose":9.36,"latestTime":"09:09 EDT","volume":65,"amount":624.4499950000001,"timestamp":1789477768349,"change":0.15,"changeRate":0.016026,"amplitude":0.014957},"postHourTrading":{"tag":"盘后","latestPrice":9.36,"preClose":9.36,"latestTime":"19:30 EDT","volume":5581,"amount":52238.16,"timestamp":1789428602377,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.907015},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","floatShares":17648000,"roa":"-36.19%","roe":"-125.02%","lyrEps":-115.29,"volumeRatio":0.907015,"shares":53984300,"dividePrice":0,"high":10.24,"amplitude":0.124466,"preClose":9.36,"low":9.075,"week52Low":7.9,"pbRate":"1.13","week52High":17.4,"institutionHeld":0,"latestPrice":9.74,"committee":-0.155844,"eps":-5.95,"divideRate":0,"volume":597070,"delay":0,"ttmEps":-5.95,"open":9.33,"prevYearClose":18,"prevWeekClose":8.94,"prevMonthClose":10.46,"prevQuarterClose":13.05,"fiveDayClose":10.71,"twentyDayClose":10.47,"sixtyDayClose":9.61},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EIKN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"EIKN","fiscalQuarterEnding":"2026/06","expectedEps":-1.61,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.63},{"market":"US","date":"2026-05-11","symbol":"EIKN","fiscalQuarterEnding":"2026/03","expectedEps":-1.47,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-2.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EIKN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EIKN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0,"sell":0,"strongSell":0.1667,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1775102400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EIKN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EIKN","date":"2026-09-14","current":-1.636975,"percent":0.886667,"low":-3.139466,"twenty":-2.084257,"median":-1.760324,"eighty":-1.536491,"high":-1.335246,"avg":-1.856783,"sd":0.375498,"marketCap":484235368},"quantilePoints":[{"date":"2026-02-06","current":-2.616222,"twenty":-3.034817,"median":-2.877844,"eighty":-2.720871,"marketCap":809765055},{"date":"2026-02-13","current":-2.586571,"twenty":-2.610292,"median":-2.537735,"eighty":-2.527619,"marketCap":800587717},{"date":"2026-02-20","current":-2.703429,"twenty":-2.7418,"median":-2.616222,"eighty":-2.529014,"marketCap":836757223},{"date":"2026-02-27","current":-2.379017,"twenty":-2.703429,"median":-2.596164,"eighty":-2.52727,"marketCap":736346356},{"date":"2026-03-06","current":-2.535991,"twenty":-2.644128,"median":-2.595292,"eighty":-2.523782,"marketCap":784932259},{"date":"2026-03-13","current":-2.054606,"twenty":-2.624942,"median":-2.562153,"eighty":-2.406924,"marketCap":635935489},{"date":"2026-03-20","current":-1.915074,"twenty":-2.616222,"median":-2.529014,"eighty":-2.298787,"marketCap":592748020},{"date":"2026-03-27","current":-1.836588,"twenty":-2.600524,"median":-2.515933,"eighty":-2.054606,"marketCap":568455068},{"date":"2026-04-02","current":-1.678228,"twenty":-2.599129,"median":-2.426109,"eighty":-1.985189,"marketCap":544162116},{"date":"2026-04-10","current":-1.504368,"twenty":-2.597385,"median":-2.379017,"eighty":-1.821565,"marketCap":487788380},{"date":"2026-04-17","current":-1.876704,"twenty":-2.595641,"median":-2.269137,"eighty":-1.751381,"marketCap":608517358},{"date":"2026-04-24","current":-1.786542,"twenty":-2.595292,"median":-2.061583,"eighty":-1.769507,"marketCap":579282538},{"date":"2026-05-01","current":-1.605383,"twenty":-2.588315,"median":-2.045013,"eighty":-1.651966,"marketCap":520542206},{"date":"2026-05-08","current":-1.531083,"twenty":-2.547502,"median":-1.986901,"eighty":-1.641614,"marketCap":496450549},{"date":"2026-05-15","current":-2.105086,"twenty":-2.53634,"median":-1.963159,"eighty":-1.651966,"marketCap":713546154},{"date":"2026-05-22","current":-1.782455,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"marketCap":604186273},{"date":"2026-05-29","current":-1.645097,"twenty":-2.527968,"median":-1.929027,"eighty":-1.650964,"marketCap":557627116},{"date":"2026-06-05","current":-1.562046,"twenty":-2.525177,"median":-1.895889,"eighty":-1.633553,"marketCap":529475781},{"date":"2026-06-12","current":-1.360801,"twenty":-2.514363,"median":-1.841551,"eighty":-1.597703,"marketCap":461261110},{"date":"2026-06-18","current":-1.55406,"twenty":-2.482968,"median":-1.809917,"eighty":-1.567693,"marketCap":526768850},{"date":"2026-06-26","current":-1.573226,"twenty":-2.429947,"median":-1.776985,"eighty":-1.53713,"marketCap":533265485},{"date":"2026-07-02","current":-1.95655,"twenty":-2.406226,"median":-1.79823,"eighty":-1.541282,"marketCap":663198193},{"date":"2026-07-10","current":-1.79204,"twenty":-2.398552,"median":-1.809917,"eighty":-1.555657,"marketCap":607435406},{"date":"2026-07-17","current":-1.589198,"twenty":-2.377273,"median":-1.784498,"eighty":-1.563963,"marketCap":538679348},{"date":"2026-07-24","current":-1.536491,"twenty":-2.355995,"median":-1.761474,"eighty":-1.543838,"marketCap":520813601},{"date":"2026-07-31","current":-1.536491,"twenty":-2.298787,"median":-1.731347,"eighty":-1.536491,"marketCap":520813601},{"date":"2026-08-07","current":-1.471006,"twenty":-2.239486,"median":-1.715581,"eighty":-1.534894,"marketCap":498616763},{"date":"2026-08-14","current":-1.736786,"twenty":-2.116266,"median":-1.712181,"eighty":-1.534894,"marketCap":559524759},{"date":"2026-08-21","current":-1.807401,"twenty":-2.105086,"median":-1.719889,"eighty":-1.534894,"marketCap":582274072},{"date":"2026-08-28","current":-1.936861,"twenty":-2.105086,"median":-1.736786,"eighty":-1.536491,"marketCap":623981145},{"date":"2026-09-04","current":-1.842708,"twenty":-2.084325,"median":-1.759483,"eighty":-1.536491,"marketCap":593648728},{"date":"2026-09-11","current":-1.54848,"twenty":-2.084271,"median":-1.760899,"eighty":-1.536491,"marketCap":498859926},{"date":"2026-09-14","current":-1.503085,"twenty":-2.084257,"median":-1.760324,"eighty":-1.536491,"marketCap":484235368}],"updateTime":1789500323891},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EIKN\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658911994","title":"營收暴增無阻英派藥業繼續虧損：預計上半年減虧三成左右！股價早已破發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911994","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658911994?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 23:03","pubTimestamp":1786460583,"startTime":"0","endTime":"0","summary":"8月11日，英派药业(07630.HK)发布盈利预告，公司预计2026年上半年收入约9470万元至1.16亿元，较去年同期约2520万元增长约276%至359%；预计期内亏损约8170万元至9990万元，较去年同期约1.29亿元减少约22%至37%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113838249182.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113838249182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["EIKN","BK1161","07630","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143932807","title":"Eikon Therapeutics宣佈晚期黑色素瘤Eik1001適應症2/3期試驗Teluride-006進入劑量選擇階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1143932807","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143932807?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 19:31","pubTimestamp":1786447878,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics今日对外披露，其针对晚期黑色素瘤开展的在研药物Eik1001，已正式进入一项名为Teluride-006的适应性2/3期临床试验的剂量选择阶段。这一里程碑标志着该研究方案向前迈出了关键一步。Eikon Therapeutics专注于开发创新疗法，以攻克难治性癌症。此次剂量选择的宣布，体现了公司对于严谨临床试验流程的坚守，以及对加速推进Eik1001临床开发进度的决心。市场分析人士正密切关注这一进展，因为若试验结果积极，Eik1001有望为晚期黑色素瘤患者群体带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181280733","title":"Eikon Therapeutics宣佈Teluride-008臨床試驗首位患者給藥，Eik1001用於非小細胞肺癌的註冊性II/III期研究正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1181280733","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181280733?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 19:32","pubTimestamp":1785151940,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics今日宣布，其在研药物Eik1001的注册性II/III期临床试验——Teluride-008，已完成首位患者给药。这项研究专注于非小细胞肺癌（NSCLC）的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116184350","title":"新聞稿：Eikon Therapeutics 宣佈任命 Ma. Fatima D. Francisco 加入董事會","url":"https://stock-news.laohu8.com/highlight/detail?id=1116184350","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116184350?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 20:04","pubTimestamp":1780920252,"startTime":"0","endTime":"0","summary":"加州米尔布雷，2026年6月8日——致力于开发创新药物以解决严重未满足医疗需求的后期临床生物制药公司 Eikon Therapeutics, Inc.  今日宣布，任命 Ma. FatimaD. Francisco 女士为公司董事会独立董事，自2026年6月15日起生效。Francisco 女士还将担任董事会薪酬委员会成员。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198302033","title":"Eikon Therapeutics公布2025年第四季度及全年財報 同步更新臨床進展與企業動態","url":"https://stock-news.laohu8.com/highlight/detail?id=1198302033","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198302033?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 19:49","pubTimestamp":1774871395,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics近日正式披露2025年第四季度及全年财务业绩报告，同时就核心临床项目进展与公司战略规划进行同步更新。此次公告全面呈现了公司在财务表现、研发管线及运营层面的最新态势。此次综合更新不仅彰显了Eikon Therapeutics以技术驱动创新的发展路径，也反映出其通过跨学科平台加速药物发现的长期承诺。公司表示将继续推进临床阶段项目的全球化布局，同时加强财务稳健性以支持未来增长计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}